Search Results

Sysmex Inostics Inc. and Genomic Testing Cooperative (GTC) formed a strategic partnership for Sysmex Inostics to commercialize GTC’s tissue and liquid biopsy solid tumors and hematology assay services to biopharma customers.

Sysmex America, Inc. announces its plan to sell hemostasis instruments and reagents to laboratories in the United States beginning in April, under the company’s mutual OEM agreement with Siemens Healthineers.

Sysmex Inostics Inc., a subsidiary of Japan’s Sysmex Corporation and Baltimore-based biotechnology firm and CLIA-certified lab, has opened submissions for its Cancer Research Excellence Program (CREP).

Sysmex Inostics Inc., a subsidiary of Japan’s Sysmex Corporation and Baltimore-based biotechnology firm and CLIA-certified lab, is exhibiting at the American Association for Cancer Research® (AACR) Annual Meeting 2023 in Orlando, FL from April 16, 2023, through April 19, 2023.

Sysmex Inostics Inc., a subsidiary of Japan’s Sysmex Corporation and Baltimore-based biotechnology firm and CLIA-certified lab, will exhibit at the Association of Molecular Pathology 2022 Annual Meeting & Expo in Phoenix Arizona from November 3, 2022, through November 5, 2022.

Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies.

Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization partnership for Sysmex’s Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023*.

Sysmex America, Inc., a leading diagnostic solutions company, has been named the exclusive distributor of vermicon identification technology System in Canada, Latin America and all the Americas.

Sysmex Inostics, Inc. and QIAGEN N.V. will co-exhibit at the 2022 ASCO Annual Meeting, the world’s largest clinical cancer research meeting, held June 3, 2022, through June 7, 2022, in Chicago.